Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B
Authors Pacheco SR, Santos MIMA, Stocker A, Zarife MAS, Schinoni MI, Paraná R, Reis MG, Silva LK
Received 23 February 2017
Accepted for publication 5 April 2017
Published 5 July 2017 Volume 2017:10 Pages 201—207
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Lucy Goodman
Peer reviewer comments 2
Editor who approved publication: Professor Suresh Antony
Sidelcina Rugieri Pacheco,1 Maria Isabel Magalhães Andrade dos Santos,1 Andreas Stocker,2 Maria Alice Sant’Anna Zarife,3 Maria Isabel Schinoni,2 Raymundo Paraná,2 Mitermayer Galvão dos Reis,1 Luciano Kalabric Silva1
1Laboratory of Pathology and Molecular Biology, Research Site Gonçalo Muniz, Foundation Oswaldo Cruz (CPqGM/Fiocruz-BA), 2Federal University of Bahia, 3Central Laboratory of Public Health of Bahia (LACEN-BA), Salvador, Brazil
Background and aims: Resistance mutation analogs to nucleos(t)ides have been described in treatment-naïve patients with chronic hepatitis B (CHB), with clinical implications. The aim of this study was to investigate primary resistance mutations and genotypes circulating in patients naïve to chronic hepatitis B, in the Northern and Northeastern regions of Brazil.
Methods: We conducted a study of resistance mutations and genotypic characterization of hepatitis B virus (HBV) in 189 treatment-naïve patients chronically infected with HBV.
Results: Drug resistance-associated mutations located in the RT domain of the P gene (rtHBV) were found in 6% of the treatment-naïve patients from the Northeastern Region. The mutations were rtA194T, rtL180M + rtM204V, rtS202I, rtM204I, and rtA181S. No patient in the Northern Region had the resistance mutation. In the gene S region, the frequency of vaccine escape mutations was 2.4% in the Northeastern Region and 8.6% in the Northern Region.
Conclusion: This information before the start of treatment may contribute to clinical decision making, reducing treatment failure and the risk of progression to cirrhosis and hepatocellular carcinoma for CHB.
Keywords: Northeast, North, Brazil, direct sequencing, treatment failure
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]